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Abstract
Background: Adiponectin is inversely related to BMI, positively correlates with insulin sensitivity, and has anti-
atherogenic effects. In recent years, adiponectin has been well studied in the field of oncology. Adiponectin has
been shown to have antiproliferative effects on gastric cancer, and adiponectin expression is inversely correlated
with clinical staging of the disease. However, no studies have reported the correlation between serum adiponectin
and receptor expression with disease progression.
Methods: In this study, we evaluated expression levels of 2 adiponectin receptors–AdipoR1 and AdipoR2–and
attempted to correlate their expression with prognosis in gastric cancer patients. AdipoR1 and AdipoR2 expression in
gastric cancer cell lines (MKN45, TMK-1, NUGC3, and NUGC4) was evaluated by western blotting analysis, and the
antiproliferative potential of adiponectin was examined in vitro. Serum adiponectin levels were evaluated in 100
gastric cancer patients, and the expression of AdipoR1 and AdipoR2 was assessed by immunohistochemical staining.
Results: MKN45 and NUGC3 expressed higher levels of AdipoR1 compared to NUGC4, even though there was no
significance in AdipoR2 expression. The antiproliferative effect of adiponectin was confirmed in MKN45 and NUGC3
at 10 μg/ml. No significant associations were observed between serum adiponectin levels and clinicopathological
characteristics, but lymphatic metastasis and peritoneal dissemination were significantly higher in the negative
AdipoR1 immunostaining group (24/32, p = 0.013 and 9/32, p = 0.042, respectively) compared to the positive
AdipoR1 group (lymphatic metastasis, 33/68; peritoneal dissemination, 8/68). On the other hand, AdipoR2
expression was only associated with histopathological type (p = 0.001). In survival analysis, the AdipoR1 positive
staining group had significantly longer survival rates than the negative staining group (p = 0.01). However,
multivariate analysis indicated that AdipoR1 was not an independent prognostic factor on patient’s survival on
gastric cancer.
Conclusions: In gastric cancer, adiponectin has the possibility to be involved in cell growth suppression via
AdipoR1. The presence of AdipoR1 could be a novel anticancer therapeutic target in gastric cancer.
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Background
As the number of obese patients increases, there is
growing interest in cytokines secreted by adipocytes.
Human adiponectin (also known as Acrp30 [1] or Adi-
poQ [2]) is a 25-kDa adipocytokine composed of 247
amino acids; adiponectin is highly and specifically
expressed in differentiated adipocytes and circulates at a
concentration of 5-10 μg/ml in the blood stream [1-5].
Serum adiponectin levels correlate with insulin sensi-
tivity and lipid metabolism [6,7]. Many studies have
reported that adiponectin is related to obesity [8], meta-
bolic syndrome [9,10], type 2 diabetes mellitus [11-13],
and arteriosclerosis [14,15]. In addition, weight reduc-
tion increases adiponectin levels in obese patients [16].
Recent studies have shown that decreased plasma adipo-
nectin levels significantly correlate with the risk of var-
ious cancers such as esophageal [17], colorectal [18],
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any medium, provided the original work is properly cited.breast [19], endometrial [20], prostate [21], renal cell
[22], and gastric cancer [23]. However, the role of adipo-
nectin in cancer etiology is not yet fully understood.
Although adiponectin may provide indirect protection
against carcinogenesis by affecting insulin sensitivity and
inflammatory states, it has direct anti-carcinogenic
effects through the AMP-activated protein kinase
(AMPK) system. Activated AMPK plays an important
role in the regulation of growth arrest and apoptosis by
stimulating p53 and p21 [24]. Moreover, independent of
AMPK activation, adiponectin decreases production of
reactive oxygen species (ROS) [25], which may result in
decreased activation of mitogen-activated-protein-kinase
(MAPK) [26] and subsequently results in inhibition of
cell proliferation.
The adiponectin receptor exists in 2 isoforms: adipo-
nectin receptor 1 (AdipoR1), which is abundantly
expressed in skeletal muscle, and adiponectin receptor 2
(AdipoR2), which is predominantly expressed in skeletal
muscle and the liver [27]. The expression of these
receptors has been reported in gastric cancer cell lines,
and adiponectin has been shown to inhibit proliferation
and peritoneal dissemination through AdipoR1/R2 acti-
vation on gastric cancer cells [28]. However, the correla-
tion between AdipoR1 or AdipoR2 expression and
overall survival rate, and the clinical importance of these
receptors remain unclear. In this study, we analyzed the
correlation between serum adiponectin levels, expression
of AdipoR1/R2, and clinicopathological characteristics as
well as overall patient survival in gastric cancer.
Methods
Reagents and cell lines
Recombinant human adiponectin was purchased from
R&D Systems, (Minneapolis, MN, USA), reconstituted
in phosphate-buffered saline (PBS) at appropriate con-
centrations and stored at 4°C until use.
Human gastric cancer cell lines, TMK-1 (poorly differ-
entiated adenocarcinoma) and MKN45 (poorly differen-
tiated adenocarcinoma) were obtained from the
American Type Culture Collection (Rockville, MD,
USA), NUGC3 (poorly differentiated adenocarcinoma)
and NUGC4 (signet ring cell carcinoma) were obtained
from the Japanese Collection of Research Bioresources
(National Institute of Health Sciences, Tokyo, Japan).
The culture medium for cells was RPMI 1640 (Gibco,
Invitrogen, Tokyo, Japan) supplemented with 10% heat-
inactivated fetal bovine serum (Nichirei Bioscience Inc.,
Tokyo, Japan), 100 IU/ml penicillin, 100 mg/ml strepto-
mycin (Gibco), and 2 mM glutamine (Nissui Pharma-
ceutical Co., Ltd., Tokyo, Japan). Cell lines were seeded
in 75-cm
2 dish flasks (Becton Dickinson, Tokyo, Japan)
and cultured in 10 mL of medium at 37°C in a humidi-
fied atmosphere of 5% CO2 in air. Cells were grown to
confluence and harvested by trypsinization with 0.25%
trypsin/EDTA (Gibco) and suspended in culture med-
ium before use.
Western blotting
Immunoblot analysis was performed as described pre-
viously [29]. Cells were lysed in RIPA buffer (50 mmol/l
pH 8.0 Tris-HCl, 150 mmol/l sodium chloride, 0.5 w/v%
sodium deoxycholate, 0.1 w/v% sodium dodecyl sulfate,
and 1.0 w/v% NP-40 substitute) (Wako, Tokyo, Japan)
containing 1% protease inhibitor cocktail (Sigma-Aldrich,
St. Louis, MO, USA). The protein concentration of each
sample was measured using a BCA protein assay kit
(Pierce Biotechnology, Rockford, IL, USA). Whole-cell
lysates were prepared in denaturing SDS sample buffer
and subjected to SDS-PAGE (ATTO Co. Ltd., Tokyo,
Japan). Proteins were transferred to PVDF membranes
(Bio-Rad Laboratories, Hercules, CA, USA) and then
blocked with commercial gradient buffer (EzBlock; Atto
Corporation, Tokyo, Japan) at room temperature for 30
min. The immunoblots were visualized using an ECL
Plus kit (GE Healthcare UK Ltd., Tokyo, Japan). The
antibody-antigen complex was detected using an ECL
Western-Blotting detection kit (GE Healthcare) and the
Light-Capture system (ATTO), and then quantified using
the CS analyzer program (ATTO). All experiments were
repeated three times. We used the following primary
antibodies: anti-AdipoR1 antibody (C-14, goat polyclonal
IgG, diluted 1:100; Santa Cruz Biotechnology Inc., Santa
Cruz, CA, USA), anti-AdipoR2 (C-12, goat polyclonal
IgG, diluted 1:100; Santa Cruz), and anti-b-actin (AC-15,
mouse monoclonal IgG, diluted 1:10,000; Sigma-Aldrich).
Cell growth assay
The viability of gastric cancer cell lines treated with adi-
ponectin was determined by standard 3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide
(MTT) assay. Cell were seeded at 5 × 10
3 cells per well
in 96-well plates and incubated overnight at 37°C. After
incubation, the supernatant was discarded and replaced
with fresh serum-free culture medium. Adiponectin was
dissolved in PBS and added to the cell culture medium
at various concentrations (0, 0.1, 1, 5, or 10 μg/ml). At
48 h after exposure to adiponectin, the supernatant was
discarded, and MTT solution was added to each well
(500 μg/mL, final concentrations) and incubated at 37°C
for 3 h. The supernatant was removed, and 150 μLo f
dimethylsulfoxide (DMSO: Wako, Japan) was added.
The absorbance of the solution was read at a wavelength
of 540 nm using a microplate reader (BIO-RAD550;
BIO-RAD, Tokyo, Japan). The percentage inhibition was
determined by comparing the cell density of the drug-
treated cells with that of untreated controls. All experi-
ments were repeated at least 3 times.
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We evaluated 100 patients with gastric cancer (cases)
who were treated with curative gastrectomy and stan-
dard lymph node dissection at the Gastroenterological
Surgery Department, Kanazawa University Hospital,
Ishikawa, from 2002 to 2009. The study was approved
by the ethics committee of Kanazawa University, and
informed consent was obtained from each patient before
enrollment in this study. All resected primary tumors
and regional lymph nodes were histologically evaluated
by H&E staining according to the Japanese Classification
of Gastric Carcinoma [30]. A fasting morning blood
sample was obtained for the adiponectin assay from
each patient after admission into the study. Samples
were also obtained from 10 healthy volunteer controls.
Weight and height of each patient was recorded by
medical staff. BMI was calculated as weight in kilograms
divided by height in square meters. Medical staff mea-
sured all data.
Serum adiponectin measurement
All blood samples were immediately separated by centri-
fugation and stored at -80°C until use. A quantitative
sandwich enzyme-linked immunosorbent assay techni-
que with a Quantikine human adiponectin immunoassay
k i t( R & DS y s t e m s ,I n c . ,M i n n e a p o l i s ,N M ,U S A )w a s
used in accordance with the manufacturer’s instructions.
All experiments were performed in triplicate.
Immunohistochemical staining
All surgically obtained specimens were fixed in 10% neu-
tral buffered formalin, embedded in paraffin, and cut into
4-μm-thick serial sections. In brief, the slides were
immersed in methanol containing 0.3% H2O2 for 30 min,
blocked with 3.3% normal goat serum in PBS, and incu-
bated with the anti-AdipoR1 antibody (C-14, goat poly-
clonal IgG, diluted 1:100; Santa Cruz Biotechnology Inc.,
Santa Cruz, CA, USA) and anti-AdipoR2 (C-12, goat
polyclonal IgG, diluted 1:100; Santa Cruz) at 4°C over-
night. After the sections were washed in PBS, immunor-
eactivity was visualized by EnVision reagent (Dako Co.,
Kyoto, Japan). Slides weree x a m i n e du n d e rl o wp o w e r
(×40) to identify the brown staining precipitates within
the cytoplasm of cancer cells. Sections that showed same
or higher staining than that of the normal gastric mucosa
and more than 10% of cancerous tissue stained under a
×100 field were considered positive samples.
Statistical analysis
Values are expressed as means ± standard error (SE).
Differences in the cell growth assay were determined by
one-way analysis of variance (ANOVA). The relationship
between serum adiponectin level and BMI or clinical
stage of gastric cancer was evaluated using the Mann-
Whitney U test. Fisher exact and c
2 test were used to
evaluate statistical correlations between plasma adipo-
nectin levels, the expression of AdipoR1 or AdipoR2 in
cancerous tissues, and various clinicopathological vari-
ables. Overall survival rates were estimated using the
Kaplan-Meier method, and a log-rank test was used to
compare results between survival time and AdipoR1 or
AdipoR2 immunohistochemical expression. The influ-
ence of various clinicopathological factors, including
AdipoRs expression, on survival was assessed by the
Cox proportional hazards model (multivariate analysis)
using backward-LR methods. All statistical analyses
were performed using the computer software package
SPSS 10.0 (SPSS Inc., Chicago, IL, USA). Significance
was defined as p < 0.05.
Results
Expression of AdipoR1/R2 and effect of adiponectin on
gastric cancer cells
To determine the expression of AdipoR1/R2 in gastric
cancer cell lines, western blotting analysis was per-
formed. As shown in Figure 1A, AdipoR1/R2 were posi-
tively detected in cell lines, and compared with NUGC4,
MKN45 and NUGC3 had higher expression of AdipoR1.
On the other hand, no significant differences were
observed in expression of AdipoR2 (Figure 1B).
In MKN45 and NUGC3, adiponectin significantly sup-
pressed proliferation at 10 μg/ml (78.5% ± 3.3%, 54.9%
± 37.5%, respectively, p < 0.05). In contrast, NUGC4
and TMK-1 were slightly suppressed after 48 h exposure
of adiponectin, but the effect was not significant even at
a concentration of 10 μg/ml (Figure 2).
Serum adiponectin and clinicopathological characteristics
As shown in Figure 3, no significant differences were
observed between serum adiponectin and BMI in gastric
cancer patients. However, adiponectin concentrations
showed a tendency to decrease gradually with an
increase in BMI (Figure 3A). Compared with the control
group, no significant differences in adiponectin were
observed between tumor stages (Figure 3B).
The mean value of serum adiponectin in the control
group was 7.0 ± 2.4 μg / m l .T h e r e f o r e ,w ed i v i d e dt h e
patients into low (n = 39) and high (n = 61) groups
using a cutoff value of 7.0, and clinicopathological char-
acteristics were compared between the 2 groups (Table
1). No significant differences were observed in age, BMI,
macroscopic tumor type, depth of tumor invasion, histo-
pathological type, lymphatic invasion, venous invasion,
lymphatic metastasis, peritoneal dissemination, hemato-
genous metastasis, or tumor stages between the 2
groups. Forty-six (69.7%) of 66 male patients were cate-
gorized in the low group, whereas only 15 (44.1%) of 34
female patients were categorized in this group.
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Figure 1 The expression of AdipoR1 and AdipoR2 in human gastric cancer cell lines. (A) Western blotting analysis for AdipoR1 (42 kD),
AdipoR2 (35 kD), and b-actin (42 kD) in human gastric cancer cell lines. (B) Densitometric analysis were performed. The results are mean ± SE
values of 3 different experiments.
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Figure 2 The effect of adiponectin on cell proliferation. Cell viability was assessed after 48-h exposure to a single dose of adiponectin (0, 0.1,
1, 5, or 10 μg/ml) in serum-free medium. The results are mean ± SE values of 3 different experiments.
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Figure 3 Correlation between serum adiponectin level and body mass index or tumor stages. Correlation between serum adiponectin
level and body mass index (A) or tumor stages (B) in gastric cancer. Box plots show interquartile range (box), median (thick line), and range
(thin line).
Table 1 Correlation between serum adiponectin level and clinicopathological characteristics in gastric cancer patients.
Adiponectin high group (n = 39) Adiponectin low group (n = 61) p value
Age (y) 63.5 ± 12.1 60.6 ± 13.2 0.275
Gender
Male 20 46 0.013
Female 19 15
BMI 22.1 ± 3.6 23.4 ± 3.9 0.079
Macroscopic type
Elevated 5 6 0.642
Depressed/flat 34 55
Depth of invasion
T1 15 31 0.227
T2, T3 and T4 24 30
Histological type
differentiated 17 22 0.558
undifferentiated 23 38
Lymphatic invasion
positive 32 42 0.142
negative 7 19
Venous invasion
positive 22 33 0.821
negative 17 28
Lymphatic metastasis
positive 23 34 0.750
negative 16 27
Peritoneal dissemination
positive 9 8 0.196
negative 30 53
Hematogenous metastasis
positive 1 3 0.558
negative 38 58
Stage
I and II 26 41 0.910
III and IV 13 20
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Page 5 of 11AdipoR1/R2 expression in gastric cancer
The protein expression of AdipoR1 and AdipoR2 was
confirmed by immunostaining of surgically resected
gastric cancer tissue specimens (Figure 4). AdipoR1
and AdipoR2 were positively detected in the cytoplasm
as well as the cell membrane of cancer cells. In con-
trast, normal gastric epithelial cells did not show sig-
nificant immunoreactivity for either AdipoR1 or
AdipoR2. In some parietal cells of normal gastric
mucosa, slight reactivity was observed in AdipoR2
expression. This was in accordance with the findings
of Ishikawa et al [28].
AdipoR1 expression was significantly associated with
histopathological type (p = 0.011) (Table 2). In addition,
negative AdipoR1 immunostaining was significantly
higher in patients with lymphatic metastasis (p = 0.013;
Table 2) and peritoneal dissemination (p =0 . 0 4 2 ;T a b l e
2). On the other hand, AdipoR2 expression was also
associated with the histopathological type (p = 0.001;
Table 3). However, no significant differences were
observed in other clinicopathological characteristics
(Table 3).
Survival analysis
Survival rates according to serum adiponectin levels, the
presence or absence of AdipoR1 expression, and Adi-
poR2 expression were assessedu s i n gt h eK a p l a n - M e i e r
method. There were no significant differences in survival
rate between the groups with high and low serum adi-
ponectin levels (p = 0.8342; Figure 5).
Patients with positive AdipoR1 staining had a signifi-
cantly longer survival rate than those with negative
staining (p = 0.01; Figure 6), whereas there were no sig-
nificant differences in AdipoR2 expression between
these 2 groups (p = 0.9871; Figure 7).
Multivariate analysis indicated that only the peritoneal
dissemination was an independent prognostic factor on
patient’s survival (p = 0.001; Table 4).
A B
C D
AdipoR1
AdipoR2
Normal Cancer
Figure 4 Representative photomicrographs. Representative photomicrographs of immunohistochemical staining of AdipoR1 (A, normal
mucosa; B, cancer tissue) and AdipoR2 (C, normal mucosa; D, cancer tissue). AdipoR1 and AdipoR2 were expressed in normal gastric mucosa in
the cytoplasm as well as in the cell membrane. In gastric cancer tissues, higher intensity of immunostaining compared to normal mucosa was
considered positive. Original magnification, ×100.
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Adiponectin, which belongs to the complement 1q
family, is composed of an N-terminal collagen-like
sequence and a C-terminal globular region, is well stu-
died in the field of oncology, and its expression is inver-
sely related to weight gain [31]. Ishikawa et al. reported
that a low serum adiponectin level was associated with
an increased risk of gastric cancer, although BMI did
not differ significantly [23]. In our study, we were also
unable to detected significant differences with respect to
serum adiponectin levels and BMI. However, visceral fat
predominantly correlates with serum adiponectin levels
[32], and BMI cannot be used to distinguish fat distri-
bution (for example, subcutaneous fat versus visceral
fat); this may be the reason for the failure to find a sig-
nificant correlation between the 2 parameters. In addi-
tion, a correlation was not observed between the
amounts of serum adiponectin and clinicopathological
factors or prognosis in gastric cancer. Ishikawa et al.
indicated a tendency of an inverse correlation between
tumor stage and serum adiponectin levels, but signifi-
cant difference was not demonstrated in the current
study. With respect to clinicopathological factors, there
were significant differences in adiponectin levels accord-
ing to tumor location and differentiation [23]. Seker et
al. also reported significant difference between degrees
of tumor differentiations and adiponectin levels [33].
Gastric cancer patients tend to be cachexic with the
progression of primary disease, and this can result in
high serum adiponectin levels [34]. Consequently, it is
difficult to elucidate the clinicopathological significance
of adiponectin in gastroenterological cancer patients
because of the aforementioned contradictory relation-
ship [35]. As a result of this lack of significant differ-
ence between the clinicopathological factors and serum
adiponectin levels, it is presumed that serum adiponec-
tin levels do not contribute to prolonged survival in
gastric cancer patients.
Generally, it is expected that receptor expression is
more important than the amount of serum ligand, but
Table 2 Expression of AdipoR1 and clinicopathological characteristics in gastric cancer patients.
AdipoR1 positive (n = 68) AdipoR1 negative (n = 32) p value
Age (y) 62.7 ± 11.0 59.7 ± 16.0 0.284
Gender
Male 44 22 0.690
Female 24 10
BMI 23.3 ± 4.0 22.1 ± 3.4 0.161
Serum adiponectin (μg/ml) 7.4 ± 5.0 8.9 ± 6.1 0.193
Macroscopic type
Elevated 8 3 0.722
Depressed/flat 60 29
Depth of invasion
T1 34 12 0.242
T2, T3 and T4 34 20
Histological type
differentiated 33 7 0.011
undifferentiated 35 25
Lymphatic invasion
positive 49 25 0.519
negative 19 7
Venous invasion
positive 37 18 0.863
negative 31 14
Lymphatic metastasis
positive 33 24 0.013
negative 35 8
Peritoneal dissemination
positive 8 9 0.042
negative 60 23
Stage
I and II 49 18 0.171
III and IV 19 14
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Page 7 of 11Table 3 Expression of AdipoR2 and clinicopathological characteristics in gastric cancer patients.
AdipoR2 positive (n = 72) AdipoR2 negative (n = 28) p value
Age (y) 62.1 ± 12.3 60.7 ± 14.2 0.624
Gender
Male 52 14 0.035
Female 20 14
BMI 22.9 ± 3.9 23.1 ± 3.8 0.719
Serum adiponectin (μg/ml) 7.9 ± 5.5 8.0 ± 5.1 0.968
Macroscopic type
Elevated 10 1 0.139
Depressed/flat 62 27
Depth of invasion
T1 33 13 0.957
T2, T3 and T4 39 15
Histological type
differentiated 36 4 0.001
undifferentiated 36 24
Lymphatic invasion
positive 55 19 0.382
negative 17 9
Venous invasion
positive 41 14 0.531
negative 31 14
Lymphatic metastasis
positive 42 15 0.666
negative 30 13
Peritoneal dissemination
positive 11 6 0.462
negative 61 22
Stage
I and II 46 21 0.289
III and IV 26 7
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Figure 5 Survival curves for 100 patients with gastric cancer
after surgery, according to serum adiponectin level. There was
no significant difference between the high serum adiponectin level
group (n = 61) and the low serum adiponectin level group (n = 39).
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Figure 6 Survival curves for 100 patients with gastric cancer
after surgery, according to AdipoR1 expression. The survival rate
of patients with gastric cancer positive for AdipoR1 expression (n =
68) was significantly greater than that of patients negative for
AdipoR1 (n = 32).
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tor expression levels.
Moreover, the expression of adiponectin receptors in
gastric cancer cell lines has already been reported [28].
They also demonstrated that the inhibitory effects of
adiponectin via AdipoR1 and AdipoR2 using specifically
down-regulated experiments by siRNA. In their study,
siRNA of adipoR1 strongly abolished the effects of adi-
ponectin, although the effect of siRNA of adipoR2 was
less prominent. In our examination, adiponectin led to
growth inhibition in MKN45 and NUGC3. The two cell
lines expressed AdipoR1 strongly, even though there
were no significance in AdipoR2 expression. Therefore,
it is likely that AdipoR1 plays an important role in cell
proliferation. Although AdipoR1 and R2 are known as
receptor subtypes, the relationship between gastric can-
cer and each subtype has not yet been clarified. There-
fore, we evaluated the association between AdipoR
expression and clinicopathological characteristics. The
expression rates of both receptors were lower in histo-
pathologically undifferentiated tumor types. However,
the significant findings in our series indicate that the
AdipoR1 expression-positive group showed lower lym-
phatic metastasis and peritoneal dissemination than the
negative group. On the other hand, no clear associations
were observed between AdipoR2 expression and any of
the clinical characteristics that we evaluated. Otani et al.
[36] reported that there are no significant associations
between AdipoR1 mRNA levels and various pathological
features in gastric cancer, whereas Barresi et al. reported
longer overall survival in patients with positive Adi-
poR1/R2 expression [37]. Our clinical results reconfirm
that AdipoR1 expression inversely correlates with tumor
growth and might contributes to improvement of prog-
nosis significantly, but not independently, in gastric can-
cer patients. However, expression of AdipoR2 does not
affect prognosis, and there was no correlation between
clinicopathological factors and AdipoR2 expression.
Adiponectin can exist as a full-length or a smaller,
globular fragment. It has been proposed that the globu-
lar fragment is generated by proteolytic cleavage, and it
has recently been shown that the cleavage of adiponec-
tin by leukocyte elastase secreted from activated mono-
cytes and/or neutrophils could be responsible for the
generation of the globular adiponectin fragment [38].
On the other hand, AdipoR1 and AdipoR2 may form
both homo- and heteromultimers. Scatchard plot analy-
sis revealed that AdipoR1 is a receptor for globular adi-
ponectin, whereas AdipoR2 is a receptor for the full-
length form of adiponectin [39]. The ability of adiponec-
tin to inhibit caspase-3 mediated cell death has been
reported in various cells, including endothelial, neuro-
blastoma, and pancreatic b cells [40-42]. Park’sg r o u p
[43] demonstrated that globular adiponectin acting via
AdipoR1 could protect mouse cardiomyocytes from
apoptosis. Here, we show a cytostatic effect of adiponec-
tin via AdipoR1, but the repression of cell proliferation
via both AdipoR1- and AdipoR2-mediated AMPK has
been also reported [44].
The improvement of prognosis in gastric cancer
patients with positive AdipoR1 expression might be
affected by organ protective effects from insulin resis-
tance and inflammatory states rather than as a result of
a direct antiproliferative effect via globular adiponectin.
Conclusions
Our data suggest that adiponectin has antiproliferative
potential; however, AdipoR1 plays a more important
role in increased survival in gastric cancer patients. The
mechanisms underlying the anti-tumor effects of adipo-
nectin and the functional properties of AdipoR have not
been fully elucidated. Although further research in this
field is necessary, the presence of AdipoR1 could be a
novel anticancer therapeutic target in gastric cancer.
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